hep B

Brii Biosciences announced $155 million last week in Series C financing.

The press release said the Sino-American biotech will use the proceeds to fund clinical studies and research for its therapies for hepatitis B, Covid-19, multi-drug resistant Gram-negative bacterial infection and HIV, as well as its central nervous system disease program.

Beijing-based Sinovac announced last week that the China National Medical Products Administration has approved its 23-valent pneumococcal polysaccharide (PPSV23) shot—the company’s first bacterial vaccine licensure, according to the press release.

According to lot release data, Sinovac will compete for PPSV23 market share in China against Beijing Minhai, Chengdu Institute of Biological Products, Merck and Walvax.

In other Chinese vaccine news, Shenzhen Kangtai (BioKangtai)…

VBI Vaccines announced Monday that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for its Sci-B-Vac three-antigen hepatitis B vaccine candidate. The Massachusetts-based biotech also plans to submit a biologics license application to the U.S. FDA in “the next couple of weeks,” according to the press release.


Local media reported last week that Bharat Biotech International Limited (BBIL) is bidding to buy into an Indian government-owned vaccine center, which has reportedly failed to start production because of a “cash crunch.”

The Economic Times said it had seen a letter from BBIL to health minister Harsh Vardhan offering to invest $84 million in the Integrated Vaccines Complex in Tamil Nadu run by state company HLL Biotech Limited (HBL) in return for the opportunity to “manufacture and…

Local media reported this week that South Africa’s Biovac has won an 85 percent share of a $770 million government vaccines contract. Biovac will provide BCG, measles-containing and hep B shots, as well as Pfizer’s Prevnar 13 pneumococcal conjugate vaccine and Sanofi’s Hexaxim acellular hexavalent vaccine. GSK will supply the country’s human papillomavirus and rotavirus vaccines.

Business Day said the 3.5-year award ends months of uncertainty about Biovac’s future, which started after…

Massachusetts-based Dicerna announced an alliance last week with Roche to develop RNA interference therapeutics for hepatitis B. Roche will pay Dicerna $200 million upfront plus up to $1.5 billion in milestones, according to the company’s press release.


Roche announced this week that it is expanding its Global Access Program beyond HIV to also include diagnostic tests for TB, hepatitis B and C, and human papillomavirus.

Set up in 2014, Roche’s Global Access Program provides special pricing to low- and middle-income countries for the company’s assays, cobas Plasma Separation Card, and cobas platforms for central lab testing.

UNICEF Supply Division published last week the new prices that it is paying for hepatitis B vaccine (hep B).

Costs of a 10-dose presentation from LG Chem and Serum Institute of India (SII) increased by 43 percent (from $0.175 to $0.25 per dose) and 20 percent (from $0.20 to $0.24 per dose), respectively between 2018 and 2020.

LG Chem’s 1-dose presentation also went up 43 percent from $0.42 to $0.60 per dose, while SII’s 1-dose presentation jumped 145 percent from $0.20 per dose…

State-owned conglomerate Rostec announced last month that Russia’s ministry of health has approved its vaccine for diphtheria, tetanus, acellular pertussis, hepatitis B, and Haemophilus influenzae type B.

The vaccine, manufactured by Rostec’s National Immunobiological Company (Nacimbio), is the first domestic pentavalent vaccine approved in Russia.

A consortium of U.S. government agencies announced this week that they are launching a task force to encourage faster development and deployment of diagnostic tests during public health emergencies. The partnership—which includes the FDA and Centers for Disease Control and Prevention—said it hopes to alleviate uncertainties around implementation protocols once a diagnostic receives Emergency Use Authorization.

In other diagnostics news, Abbott also announced last week that the European…